Results 1 to 10 of about 11,407 (242)
Biomolecules, 2019 Physician awareness and perceptions towards biosimilars are important factors in their adoption to clinical practice. Our objectives were to assess levels of knowledge and attitudes towards biosimilars and key policies on their use among Russian ...
D E Karateev
exaly +3 more sources
Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan [PDF]
Journal of Pharmaceutical Policy and PracticeBackground Biosimilars present a significant opportunity for cost savings. However, the uptake of biosimilars has been inconsistent across different regions and drugs, highlighting the need for effective policy interventions.
Hiroaki Mamiya +2 more
doaj +2 more sources
Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge [PDF]
European Medical Journal Rheumatology, 2018 Biosimilars are more affordable versions of previously approved biopharmaceuticals that are designed to reduce healthcare expenditure and increase patient access to this therapeutic class. To achieve their economic potential, many European countries have
Filipe C. Araújo +2 more
doaj +1 more source
Journal of Oncology Practice, 2017 Biosimilar therapeutic proteins in oncology offer the potential to decrease costs while providing safety and efficacy profiles consistent with their respective reference or originator products. Biosimilars have a number of important differences from generic small-molecule drugs, including manufacturing processes that are unique from their reference ...
R. Donald Harvey
openaire +3 more sources
Monoclonal antibody biosimilars for cancer treatment [PDF]
iScienceSummary: Monoclonal antibodies are important cancer medicines. The European Medicines Agency (EMA) approved 48 and the Food and Drug Administration (FDA) 56 anticancer monoclonal antibody-based therapies.
Linda N. Broer +6 more
doaj +2 more sources
Biosimilars for Haematologic Malignancies: The Path to Sustainable Care
European Medical Journal Hematology, 2017 The main objectives of this symposium were to review the value of biosimilars in sustainable treatment for haematologic malignancies and to recognise the developmental differences between biosimilars and their reference products.
Paul Cornes +2 more
doaj +1 more source
ESMO Open, 2018 Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
+9 more sources
An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare
PharmaceuticalsBiological therapies have transformed high-burden treatments. As the patent and exclusivity period for biological medicines draws to a close, there is a possibility for the development and authorization of biosimilars.
Filipa Mascarenhas-Melo +2 more
exaly +3 more sources
Patient Preference and Adherence, 2017 John Waller,1 Emma Sullivan,1 James Piercy,1 Christopher M Black,2 Sumesh Kachroo2 1Adelphi Real World, Manchester, UK; 2Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA Objectives: We examined ...
Waller J +4 more
doaj +1 more source
Biosimilars in rheumatoid arthritis in 2022 – data from the Romanian Registry of Rheumatic Diseases [PDF]
Romanian Journal of Rheumatology, 2023 Objective. The study aimed at determining whether RA patients starting or stopping biosimilars differ in any regard from those starting or stopping originals. Methods.
Horatiu Popoviciu +8 more
doaj +1 more source